Date: Wednesday, December 3, 2025
Time: 9:00am – 5:00pm
Location: The Langham, London Fitzrovia Room Ic Portland Place London W1B 1JA
This event leads into RESI London, where we are proud sponsors on December 4. The conference brings together early-stage biotech innovators, investors, and strategic partners, including entrepreneurs, venture capital firms, licensing partners, and service providers, who share a commitment to advancing promising science into impactful therapies.
What is Certara’s Biotech Forum?
On December 3, ahead of the RESI London conference, we are hosting Certara’s Biotech Forum, an exclusive workshop for biotech executives, founders, and investors. The session is designed to help leaders in emerging biotech strengthen their development strategy, improve the odds of bringing therapies successfully to market, and navigate the critical early stages of development where strategic pitfalls often lead to costly delays, investor hesitation, or program failure.
Submit your request to register
Agenda
Discover how early missteps in development strategy can derail timelines, erode investor confidence, and prevent launch success.
Moderator: Matthias Breugelmans, Vice President, Global Head of Research & Development, Mundipharma
Panelist: Marc Daigneault, Venture Building Lead, Catapult Medicines Discovery
Gain insider perspective on current trends, common pitfalls, and what investors really look for in emerging biotech companies.
Learn how to identify and evaluate therapeutic potential to select the right candidate with the greatest chance of success.
Secure your spot for one-on-one sessions with Certara experts and connect with peers over lunch.
Panelist: Matthias Breugelmans, Vice President, Global Head of Research & Development, Mundipharma
See how to build a development roadmap that balances science, regulation, and commercial potential to deliver on investor expectations.
Panelist: Ian Wilson, PhD, Vice Chairman, ImaginAb Inc.
Hear from biotech leaders, investors, pharma, and Certara experts on how early strategic decisions shape risk, speed, and fundability.
Join interactive breakout stations with Certara’s experts in modeling, clinical pharmacology, regulatory, and commercial strategy to explore solutions for your challenges.
Recap key insights and learn how to continue the conversation with Certara’s experts.
Vice President, Global Head of Research & Development, Mundipharma
Matthias Breugelmans is a seasoned R&D executive and entrepreneur with a career spanning leadership roles across the pharmaceutical, biotech, diagnostics, and digital health sectors. As VP and Global Head of Research & Development at Mundipharma, he leads a global team across Clinical Development & Operations, Data Science, Consumer Health, and R&D Strategy, driving innovation with the patient at heart.
Matthias is also a partner at SLS Capital, where he supports startups and academic spinouts in scaling breakthrough technologies through strategic investment and operational guidance. His entrepreneurial journey includes co-founding True Nature, leading Elastrin Therapeutics, a biotech company pioneering nanoparticle-based therapies for life-threatening diseases, and organizing DxPx, a global partnering conference for diagnostics and precision medicine.
With a track record of transforming R&D organizations, securing funding, and accelerating development timelines, Matthias offers a blend of scientific insight, operational excellence, and leadership. He is a frequent speaker on innovation strategy, translational science, and the future of healthcare.
Venture Building Lead
Catapult Medicines Discovery
Marc Daigneault is New Venture Lead at Medicines Discovery Catapult, specializing in life science innovation and funding strategy. He has secured over £100 million in public funding for high-impact R&D across Europe, catalyzing more than £900 million in private investment and corporate partnerships. With an M.Sc. and Ph.D. in cellular and molecular biology, and deep expertise in infection and immunology, Marc combines scientific insight with commercial acumen to support ventures that translate cutting-edge research into scalable, investable opportunities.
Vice Chairman, ImaginAb Inc.
Ian Wilson received his PhD from Cambridge University and has over 30 years of experience in the commercial development of in vivo medical diagnostics and imaging medical devices. Ian is currently the Vice Chairman of ImaginAb Inc, an imaging and radiotherapy company developing next generation molecular imaging agents using the minibody technology. Before joining ImaginAb, Ian was the CEO and CTO of Edinburgh Molecular Imaging Ltd., leading the development of novel optical imaging agents to improve cancer detection, surgery, and lung disease.
In a previous position at Xstrahl Ltd., as CTO & COO, Ian was responsible for the oversight of Radiotherapy commercial operations and manufacturing, including new product development. Between 1996 and 2013, Ian held numerous roles at GE Healthcare including Portfolio and Strategy Manager and Head of Biology. While at GE Healthcare, Ian was responsible for the management of GE Healthcare’s Molecular Imaging Agent Portfolio, in Cardiovascular, Oncology & Neurology, and strategic as well as tactical oversight. Ian was also responsible for supporting the efficacy and regulatory studies required for the approval of new imaging agents.
Submit your request to register
